Romina Quercia, M.D., Ph.D.

Pfizer
London, England, United Kingdom

Disclosure(s): Pfizer: Employee, Stocks/Bonds (Public Company)

Presentation(s):

• 88 - Efficacy of nirmatrelvir-ritonavir in high-risk trial participants with prior SARS-CoV-2 infection or vaccination: a pooled analysis

  Thursday, October 17, 2024
  10:42 AM – 10:54 AM US PT